NATCOPHARMNatco Pharma Ltd.

    Natco Pharma Q2 FY27 Results: Consolidated Net Profit ₹203 Crore on Total Income of ₹1,019 Crore

    • Earnings
    • Pharmaceuticals
    A hand holding several capsules and tablets in red, green, white and yellow against a green background
    guvo59, via Wikimedia Commons (CC0). Illustrative image.

    Natco Pharma (NSE: NATCOPHARM) reported consolidated total income of ₹1,019 crore and net profit of ₹203 crore for the quarter ended 30 Sep 2026, it said in a filing on 13 Nov 2026. Standalone total income was ₹895 crore and standalone net profit ₹143 crore for the same quarter.

    Key highlights

    Consolidated

    Including its subsidiaries

    • Total income: ₹1,019 crore, down 30.3% YoY and up 28.3% QoQ
    • Net profit and EPS: ₹203 crore, down 60.9% YoY and 1.9% QoQ; basic EPS ₹11.31
    • Share of associate: ₹29.2 crore from Adcock Ingram, 49% holding after a 13.25% stake addition
    • Finance costs: ₹18 crore, up 34.4% YoY

    Standalone

    The company on its own, without its subsidiaries

    • Total income: ₹895 crore, down 34.1% YoY and up 38.8% QoQ
    • Net profit and EPS: ₹143 crore, down 71.4% YoY and up 92.0% QoQ; basic EPS ₹8.00
    • Profit before tax: ₹197 crore, down 66.4% YoY

    Summary

    Consolidated ₹ crore
    ParticularsQ2 FY27Q2 FY26YoYQ1 FY27QoQ
    1,0191,463-30.3%794+28.3%
    203518-60.9%207-1.9%
    EPS, basic (₹)11.3128.94-60.9%11.53-1.9%

    Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.

    Consolidated net profit fell 60.9% YoY, more than total income, which fell 30.3%. Profit before tax fell 60.4%, so the steeper drop in net profit sits below the pre-tax line in the figures shown. Tax expense fell 27.1% to ₹70 crore.

    The press release attributes the QoQ revenue increase to better performance in the International Formulation business, and the YoY decline largely to lower Lenalidomide revenue. Revenue from operations fell 29.0% YoY, less than other income, which fell 47.9%. Other income of ₹52.10 crore is 21.4% of profit before tax of ₹243.20 crore.

    Net profit fell 1.9% QoQ while total income rose 28.3%. The filing's consolidated figures include a share of profit of associate of ₹29.2 crore, which the press release says is after a provisional PPA adjustment. Finance costs of ₹18 crore are 1.8% of total income, up 34.4% YoY.

    Standalone ₹ crore
    ParticularsQ2 FY27Q2 FY26YoYQ1 FY27QoQ
    8951,358-34.1%645+38.8%
    143501-71.4%75+92.0%
    EPS, basic (₹)8.0027.97-71.4%4.17+91.8%

    Figures are in ₹ crore; YoY compares with Q2 FY26 and QoQ with Q1 FY27. Click Total income or Net profit to see the rows behind them.

    Standalone net profit fell 71.4% YoY, more than total income, which fell 34.1%. Standalone profit before tax fell 66.4%, and tax expense fell 36.8% to ₹54 crore. Standalone other income of ₹40.30 crore is 20.5% of profit before tax of ₹197.00 crore.

    Against the prior quarter, standalone net profit rose 92.0%, faster than total income at 38.8%. Standalone revenue from operations rose 43.2% QoQ. Standalone net profit of ₹143 crore is ₹60 crore below the consolidated figure of ₹203 crore; the filing's consolidated results also include subsidiaries and the associate, and the notes do not break that gap down.

    Consolidated net profit (₹203 crore) is ₹60 crore higher than standalone (₹143 crore), while consolidated total income (₹1,019 crore) is ₹124 crore higher than standalone (₹895 crore). Both sets of results carry an unmodified review report from B S R and Co, and the consolidated review relies in part on other auditors' reports for 13 subsidiaries and step-down subsidiaries.

    Inference

    The board declared a second interim dividend of ₹1.25 per equity share of ₹2 face value (62.50%) for FY 2026-27 on 13 Nov 2026, with a record date of 19 Nov 2026 and payment starting 27 Nov 2026. The earlier interim dividend of ₹1.5 per share for the quarter ended 30 Jun 2026 was approved on 14 Aug 2026.

    The company acquired a further 13.25% of Adcock Ingram for a total consideration of ₹1,060 crore, and says its stake is now 49%. The notes give the completion date differently in the consolidated and standalone sets, and the filing does not say how the acquisition is funded beyond the consideration shown. The filing also does not say how much the rights issue raised or how the proceeds will be used.

    The scheme of arrangement transferring the crop protection business to NATCO Crop Health Sciences Limited is being revised alongside the rights issue, and filings with regulators are in process; the filing does not give the reason for the change beyond keeping the share swap ratio the same.

    Filed with BSE on . Reference: Original filing (PDF)

    Disclaimer:

    The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

    Related posts

    All Natco Pharma Ltd. articles